The discovery of ketamine as a rapid-acting antidepressant led to a new era in the
development of neuropsychiatric therapeutics, one characterized by an antidepressant …

Background Recently intermittent theta burst stimulation (iTBS) proved to be non-inferior to
conventional repetitive transcranial magnetic stimulation (10 Hz rTMS) in unipolar …

Background Though intravenous (IV) ketamine and intranasal (IN) esketamine are noted to
be efficacious for treatment-resistant depression (TRD), access to each of these treatments …

Changes in Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) channel function
have been linked to depressive-like traits, making them potential drug targets. However …

Background Ketamine and its enantiomer esketamine represent promising new treatments
for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive …

Introduction The purpose of this update is to add newly approved nomenclatures and
treatments as well as treatments yet to be approved in major depressive disorder, thus …

Abstract Introduction Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS)
are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies …

Introduction Major depressive disorder (MDD) is more likely to resist to usual treatment when
it is associated with post-traumatic stress disorder (PTSD). Capitalizing on the effect of …

Some psychiatric patients have exhausted all approved treatment options. Numerous
investigational drugs are currently being developed and tested in clinical trials. However, not …

Ketamine and its enantiomers represent an innovative glutamatergic agent as a treatment
for individuals with treatment-resistant depression (TRD) and major depressive disorder …